In the future, we will investigate whether the abnormal metabolic indicators, insulin resistance, and PRL levels of co-DM patients have a deeper unexplored influence mechanism on the protective effect of aripiprazole on hyper-prolactin. The gene discussed is PRL; the disease is diabetes mellitus.